



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	<b>ATTY. DOCKET NO.</b> 11245/46605	<b>SERIAL NO.</b> 09/996,954
	<b>APPLICANT</b> WAKSAL et al.	
	<b>FILING DATE</b> November 30, 2001	<b>GROUP</b> 1642 1643

## U. S. PATENT DOCUMENTS

\* reference enclosed

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
Alt	* 5,616,582	April 1, 1997	Barker			
Alt	* 5,558,864	September 24, 1996	Bendig et al.			
Alt	5,891,996	April 6, 1999	Mateo de Acosta del Rio et al			
Alt	6,217,866	April 17, 2001	Schlessinger et al.			
Alt	U.S. Application Serial No. 09/809,924	Filed March 16, 2001	Rubin			

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
Alt	WO 98/03106	June 2, 2000		PCT			
Alt	WO 98/03798	August 6, 1998		PCT			
Alt	WO 97/02181	November 13, 1997		PCT			
Alt	WO 97/00034	August 21, 1997		PCT			
Alt	WO 97/02700	July 11, 1997		PCT			
Alt	WO 96/33988	October 31, 1996		PCT			
Alt	WO 96/30347	October 3, 1996		PCT			

## OTHER DOCUMENTS

\* reference enclosed


EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
Alt	* Moyer et al., "Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, in an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase" Cancer Res., vol. 57, No. 21, November 1, 1997 pp. 4838-4848
Alt	* Pollack et al., "Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358, 774: Dynamics of Receptor Inhibition in Situ and Antitumor Effects in Athymic Mice", J. Pharmacol., vol. 291, No. 2, November 1999, pp 739-748
Alt	* Rowinsky, et al., "Dose-Schedule-Finding, Pharmacokinetic (PK), Biologic, and Functional Imaging studies of OSI-774, a Selective Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase (TK) Inhibitor", Abstract 5 (Presented at the 37 <sup>th</sup> Annual Meeting of ASCO), San Francisco, CA, 12-15 May 2001
Alt	* Anido et al., "Inhibition by ZD1839 (Iressa) of Epidermal Growth Factor (EGF) and Heregulin Induced Signaling Pathways in Human Breast Cancer Cells", Abstract 1712 (Presented at the 37 <sup>th</sup> Annual Meeting of ASCO), San Francisco, CA 12-15 May 2001



EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
Alt	* Hidalgo et al., "Inhibition of the Epidermal Growth Factor Receptor (EGFR) by OSI-774, A specific EGFR Inhibitor in Malignant and Normal Tissues of Cancer Patients", Abstract 281 (Presented at the 37th Annual Meeting of ASCO), San Francisco, CA, 12-15 May 2001
Alt	* Punt, "New Drugs in the Treatment of Colorectal Carcinoma", Cancer, Vol. 83, No. 4, August 15, 1998, pp.679-689
Alt	Y. Han, et al. "Preferential Inhibition of Glioblastoma Cells with Wild-Type Epidermal Growth Factor Receptors by a Novel Tyrosine Kinase Inhibitor Ethyl-2,5-Dihydroxycinnamate", Oncology Research, vol. 9, 1997, pp. 581-587
Alt	C.R. Divgi, et al. "Phase I and Imaging Trial of Indium 111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in Patients with Squamous Cell Lung Carcinoma", Journal of Nat'l Cancer Institute, vol. 83, no. 2, January 16, 1991, pp. 97-104
Alt	A. B. Miller et al., "Reporting Results of Cancer Treatment", Cancer, vol. 47, no. 1, January 1, 1981, pp. 207-214
Alt	Stedman's Medical Dictionary, 25th Edition, p. 1338, 1990.
Alt	Pfister, et al., Abstract, 1667, 35th Annual Meeting of ASCO, 1999
Alt	Siu, et al., Abstract, 1498, 35th Annual Meeting of ASCO, 1999

\* reference enclosed

EXAMINER	Anne L. Holleran	DATE CONSIDERED	3/6/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT  
BY APPLICANT PTO-1449**

ATTY. DOCKET NO.  
11245/46605

SERIAL NO.  
09/996,954

APPLICANT  
WAKSAL et al.

FILING DATE  
November 30, 2001

GROUP  
1642 1643

RECEIVED  
SEP 28 2003  
TECH CENTER 1600/2900

**U. S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
Alt	6,605,448	August 12, 2003	Pieczenik			
Alt	5,866,363	February 2, 1999	Pieczenik			

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER'S INITIALS		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	<i>Michael R. Ballman</i>	DATE CONSIDERED	<i>2/16/06</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	<b>ATTY. DOCKET NO.</b> 11245/46604	<b>SERIAL NO.</b> 09/374,028
	<b>APPLICANT</b> H. WAKSAL	
	<b>FILING DATE</b> August 13, 1999	<b>GROUP</b> 1642/643

JCE87 U.S. PTO  
 09/996954  
 11/23/01

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
<del>AUH</del>	6,217,866	<del>April 7, 1999</del>	<del>Schlessinger</del>			
<del>AUH</del>	5,891,996	<del>April 6, 1999</del>	<del>Acosta del Rio et al.</del>			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<del>AUH</del>	WO 00/31048	June 2, 2000	PCT				
<del>AUH</del>	WO 98/33798	August 6, 1998	PCT				
<del>AUH</del>	WO 97/42187	November 13, 1997	PCT				
<del>AUH</del>	WO 97/30034	August 21, 1997	PCT				
<del>AUH</del>	WO 97/27199	July 31, 1997	PCT				
<del>AUH</del>	WO 96/33980	October 31, 1996	PCT				
<del>AUH</del>	WO 96/30347	October 3, 1996	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
<del>AUH</del>	<del>Y. Han, et al. "Preferential Inhibition of Glioblastoma Cells with Wild Type Epidermal Growth Factor Receptors by a Novel Tyrosine Kinase Inhibitor Ethyl-2,5-Dihydroxycinnamate". Oncology Research, vol. 9, 1997, pp. 581-587</del>
<del>AUH</del>	<del>C.R. Divgi, et al. "Phase I and Imaging Trial of Indium-111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in Patients with Squamous Cell Lung Carcinoma". Journal of Nat'l Cancer Institute, vol. 83, no. 2, January 16, 1991, pp. 97-104</del>
<del>AUH</del>	<del>A. B. Miller et al., "Reporting Results of Cancer Treatment", Cancer, vol. 47, no. 1, January 1, 1991, pp. 207-214</del>
<del>AUH</del>	<del>Stedman's Medical Dictionary, 25th Edition, p. 1338</del>
	<del>Phister, et al., Abstract, 1667, 35th Annual Meeting of ASCO, 1999</del>
	<del>Siu, et al., Abstract, 1498, 35th Annual Meeting of ASCO, 1999</del>

<b>EXAMINER</b> Anne L. Hillman	<b>DATE CONSIDERED</b> 3/6/2006
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	